AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie has delivered strong returns and dividend growth, with solid prospects but notable risks creating near-term ...

Alphabet drives cloud and AI momentum, Exxon Mobil boosts energy projects, and AbbVie rides strong drug launches despite ...

Alphabet, Exxon Mobil, and AbbVie remain Zacks' top coverage picks as each navigates industry shifts while driving long-term ...

AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

AbbVie Inc. (NYSE:ABBV) exceeded sales expectations with a $260 million overachievement in Q3 2024, driven by strong growth from its ex-Humira platform, including Skyrizi and Rinvoq, which are ...

This was the stock's second consecutive day of gains.

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...